Key result
Moxonidine lowers SBP by ~10%, outperforming telmisartan in hypertensive patients.
Why the study?
Does moxonidine compared to telmisartan improve blood pressure, insulin resistance, and lipid profiles in hypertensive patients?
RCT (n=60)
Open-label
1:1
No
Does moxonidine compared to telmisartan improve blood pressure, insulin resistance, and lipid profiles in hypertensive patients?
Moxonidine may provide slightly greater blood pressure reduction than telmisartan in hypertensive patients, though telmisartan has more favorable effects on total cholesterol and LDL-C.
Answers are grounded in this paper and cite their sources.
Moxonidine achieved modestly greater SBP reduction than telmisartan; extends comparative RCT data in hypertension while highlighting lipid trade-offs.
Background: Hypertension being a major cause of cardiovascular diseases worldwide is associated with the overactivation of Renin Angiotensin System (RAS). Both hypertension and insulin resistance are important components of metabolic syndrome and a strong association exists between these two. Some of Previous studies conducted on Moxonidine and Telmisartan suggest, these agents have a better efficacy and safety profile than other antihypertensives The present study is an effort to focus on the effectiveness of these drugs on hypertensive people of Majha region of Punjab, India. Aim: To compare the effects of both drugs as monotherapy on the various parameters of blood pressure, insulin resistance and lipid profile. Material and Methods: It was a randomized (1:1), open label, parallel, comparative study. Moxonidine 0.3 mg in one group (A) (n=30) and telmisartan 40 mg in other group (B) (n=30) were used daily for 12 weeks in hypertensive patients. Patients were evaluated at day 0 and at 12 weeks. Results: Fall in SBP levels by 9.5% in group-A and 7.4% in group-B (p<0.0001) was observed while DBP levels decreased by 8.9% (p<0.0001) in group A and by 5.6% (p<0.01) in group B. HOMA-IR value was drop by 7.0 % and 7.2 % in group A and B respectively. A mean fall of 8% in TC levels (p<0.0001) and a mean fall of 10 % in LDL-C levels was observed in group B. In group A, reduction of 12.5 % (p<0.0001) in TG levels was observed. BP goal to achieve SBP <140 mm Hg and DBP < 90 was attained in 24 patients in group A and 20 patients in group B.Conclusion: Moxonidine is slightly better as an antihypertensive than Telmisartan. At the same time, telmisartan has additional favourable effects on lipid profile (total cholesterol, LDL-C)
No takes yet. Share an insight, caveat, or question.
Rajan et al. (2015) conducted an RCT in Hypertension (n=60). Moxonidine vs. Telmisartan 40 mg daily was evaluated on Mean percentage change in systolic blood pressure at 12 weeks (p=0.02). Moxonidine 0.3 mg daily reduced systolic blood pressure by 9.5% compared to a 7.4% reduction with telmisartan 40 mg daily in hypertensive patients over 12 weeks.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: